• Citer

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial

par Baselga, José;Greger, James J.G.;Abdel Azim, Hatem Hamdy ;Piccart-Gebhart, Martine ;de Azambuja, Evandro ;Dinh, Phuong ;Vuylsteke, Peter;Agbor-Tarh, Dominique;Bradbury, Ian;Smith, Ian;Di Cosimo, Serena;Jackisch, Christian;Aktas, Bahriye;Eidtmann, Holger;Kim, Sung-Bae;Huang, Chiun Sheng;Hsieh, Ruey Kuen;Dreosti, Lydia
Référence Journal of clinical oncology, 31, 36, page (4504-4511)
Publication Publié, 2013

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Purpose We investigated the pattern of rash, diarrhea, and hepatic adverse events (AEs) secondary to lapatinib and their association with age and pathologic complete response (pCR) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALLTO) phase III trial. Patients and Methods Patients with HER2-positive early breast cancer were randomly assigned to receive lapatinib (Arm A), trastuzumab (Arm B), or their combination (Arm C) for 6 weeks followed by the addition of paclitaxel for 12 weeks before surgery. We investigated the frequency and time to developing each AE according to age (≤ 50 v > 50 years) and their association with pCR in a logistic regression model adjusted for age, hormone receptors, tumor size, nodal status, planned breast surgery, completion of lapatinib administration, and treatment arm. Results Only patients randomly assigned to arms A and C were eligible (n = 306). Younger patients (≤ 50 years) experienced significantly more rash compared with older patients (74.4% v 47.9%; P < .0001). Diarrhea and hepatic AEs were observed in 78.8% and 41.2% of patients, respectively, with no differences in rate or severity or time of onset according to age. Early rash (ie, before starting paclitaxel) was independently associated with a higher chance of pCR, mainly in patients older than 50 years (odds ratio [OR] = 3.76; 95% CI, 1.69 to 8.34) but not in those ≤ 50 years (OR = 0.92; 95% CI, 0.45 to 1.88; P for interaction = .01). No significant association was observed between pCR and diarrhea or hepatic AEs. Conclusion Our results indicate that the frequency and clinical relevance of lapatinib-related rash is largely dependent on patient age. © 2013 by American Society of Clinical Oncology.